A5028545414- Herpesvirus Infections and Treatments
- Spectroscopy Techniques in Biomedical and Chemical Research
- Advancements in Transdermal Drug Delivery
- Skin and Cellular Biology Research
- Poxvirus research and outbreaks
- Microfluidic and Capillary Electrophoresis Applications
- Healthcare and Venom Research
- Dermatology and Skin Diseases
- Virus-based gene therapy research
- Bartonella species infections research
- Microbial Inactivation Methods
- thermodynamics and calorimetric analyses
- Renal and related cancers
- Viral Infectious Diseases and Gene Expression in Insects
- Lipid Membrane Structure and Behavior
- Advanced Drug Delivery Systems
- Bee Products Chemical Analysis
- Acute Lymphoblastic Leukemia research
- Antibiotics Pharmacokinetics and Efficacy
- Acne and Rosacea Treatments and Effects
- Plant Reproductive Biology
- Microfluidic and Bio-sensing Technologies
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Pesticide Residue Analysis and Safety
GlaxoSmithKline (Belgium)
2009-2020
UCLouvain
2004-2009
Institut Universitaire de Recherche Clinique
2004
In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes in adults ≥50 years age. Solicited adverse events (AEs) were collected for 7 days post-each dose a study sub-cohort. The incidence reported solicited AEs was higher RZV compared to placebo recipients. Since reactogenicity may contribute person's willingness be vaccinated, knowing about expected might help keep high...
Herpes zoster (HZ) risk appears to vary by sex and geographic ancestry/ethnicity.In 2 randomized clinical trials, participants received doses of adjuvanted recombinant vaccine (RZV) or placebo intramuscularly, months apart. In this post-hoc analysis, we investigate efficacy RZV against HZ postherpetic neuralgia (PHN) sex, region, ancestry/ethnicity in ≥50-year-olds (ZOE-50: NCT01165177) ≥70-year-olds (pooled data from ZOE-50 ZOE-70: NCT01165229).Vaccine PHN was similar women men. Across...
This Phase I, multicenter, randomized study (ClinicalTrials.gov NCT01220128) evaluated the safety and immunogenicity of recombinant Wilms' tumor 1 (WT1) protein combined with immunostimulant AS15 (WT1-immunotherapeutic) as neoadjuvant therapy administered concurrently standard treatments in WT1-positive breast cancer patients. Patients were treated 4 cohorts according to treatment (A: post-menopausal, hormone receptor [HR]-positive patients receiving aromatase inhibitors; B: chemotherapy; C:...
Abstract Background In the pivotal clinical trials, ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229), adjuvanted recombinant zoster vaccine (RZV) showed high efficacy against herpes postherpetic neuralgia. The incidence of reported solicited events was higher in RZV compared with placebo recipients. Methods these phase III, observer-blind, placebo-controlled trials conducted 18 countries, adults ≥50 years age (YOA, ZOE-50) ≥70 YOA (ZOE-70), randomized 1:1, received 2 doses or months apart....
Abstract Background The risk of herpes zoster (HZ) has been reported to vary by sex and ethnicity. In 2 large-scale clinical trials, ZOE-50 (NCT01165177) ZOE-70 (NCT01165229), the adjuvanted recombinant vaccine (RZV) demonstrated high efficacy (VE) against HZ post-herpetic neuralgia (PHN). We present a post-hoc analysis RZV PHN in ZOE-50/70 population stratified sex, geographic region ancestry/ethnicity. Methods studies were phase III, observer-blind, placebo-controlled trials conducted...